Hydroxyurea is an affordable drug that reduces vaso-occlusive crises and transfusion requirements in sickle cell disease
For some children and teenagers, a stem cell transplant might cure the disease
We identified and synthesised the reported implementation outcomes for the therapeutic use of hydroxyurea for SCD in these settings
Etiology of Sickle Cell Anemia
Current trends and research findings related to improving the prognosis of children with SCD are offered
Red blood cells contain hemoglobin, a protein that carries oxygen
1 – 3 The pathologic hallmarks of the disease are vaso-occlusion, chronic hemolysis, and increased erythrocyte adhesiveness to vascular endothelium
Hydroxyurea is an oral therapeutic agent with proven laboratory and clinical efficacy for sickle cell anemia
View PDF
Background: Sickle cell disease (SCD) is one of the commonest severe monogenic disorders in the world, due to the inheritance of two abnormal haemoglobin (beta globin) genes
Interventions to treat sickle cell anemia, or to lessen symptoms associated with the disease include: maintaining adequate hydration and oxygenation, analgesics and warm compresses for pain
Sickle cell disease (SCD) is an autosomal recessive condition in which red blood cells become sickle-shaped and fragile
Occurs mainly in persons of African descent
SCA is homozygous and the patient must have two abnormal alleles present to have sickle cell anemia
2°F
Hydroxyurea is an underutilized evidence-based medication that reduces complications and improves survival in SCD